Frontlight ResearchEarly access
CompletedPhase 1/2
Montmorency Cherry Supplementation, Sleep, and Inflammation
Key facts
- Who runs it
- Michigan State University
- Where
- East Lansing, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 1/2
- People taking part
- 34 people enrolled
- Started
- 18 Feb 2023
- Ended
- 17 Apr 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Montmorency cherry supplement
- Control
- Record updated
- 8 September 2025
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- body mass index (BMI) of ≥ 25.0 kg/m2
- sleep issues as identified by a global score of 5 or greater on the Pittsburgh Sleep Quality Index (PSQI) and/or a score 8 or higher on the Insomnia Severity Index (ISI)
- ability to adhere to a diet low in antioxidants during the study period; and
- willingness to wear a Fitbit for the duration of the study and to wear the Zmachine on selected nights
Who cannot take part
- unwilling or unable to stop the use of sleep medication
- unable to attend laboratory visits on the East Lansing, Michigan campus
Where in United States
- Michigan State UniversityEast Lansing, United States
About the trial
What the trial wants to find out
This study will test the effects of Montmorency cherry supplementation on sleep outcomes and inflammatory biomarkers.
The 2 groups in the trial
- InterventionTreatment being tested
500 mg cherry supplement
Treatment: Montmorency cherry supplement
- ControlPlacebo, for comparison
Placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Montmorency Cherry Supplementation on Sleep and Inflammatory Outcomes
- Record updated
- 8 September 2025